Gallium-68 DOTATOC

Drug Profile

Gallium-68 DOTATOC

Alternative Names: 68Ga-DOTA-tyr3-Octreotide; 68Ga-DOTATOC; SomaKit-TOC

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer Advanced Accelerator Applications; Icahn School of Medicine at Mount Sinai; National Cancer Institute (USA); Turku University Hospital; University of Iowa
  • Class Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Neuroendocrine tumours
  • Phase II/III Glioma

Most Recent Events

  • 09 Jan 2017 Registered for Neuroendocrine tumours (Diagnosis) in European Union (IV)
  • 04 Jan 2017 The National Institutes of Health, National Cancer Institute and the University of Iowa plan a phase II trial for Neuroendocrine tumours (Diagnosis, In infants, In children, In adolescents, In adults, In the elderly) in USA (NCT03013387)
  • 20 Dec 2016 M.D. Anderson Cancer Center initiates an expanded-access programme for Neuroendocrine tumours (Diagnosis) in USA before December 2016 (NCT03001349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top